Search
Maze Therapeutics Inc
MAZEAdd to Watchlist
23.810USD
+0.240+1.02%
Market hours （ET）Quotes delayed by 15 min
1.18BMarket Cap
LossP/E TTM
More Details of Maze Therapeutics Inc Company
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in harnessing the power of human genetics and variant functionalization with its Maze Compass platform to develop small-molecule precision medicines for the treatment of renal, cardiovascular and related metabolic diseases, including obesity. The Compass platform has been purpose-built to inform all phases of drug discovery and development process through clinical trial design, advancing two wholly owned lead programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach to chronic kidney disease (CKD). Its lead program, MZE829, is an oral, small-molecule inhibitor of apolipoprotein L1, or APOL1, for the treatment of patients with APOL1 kidney disease, or AKD. Its second lead program, MZE782, is an oral, small-molecule inhibitor of the solute transporter SLC6A19, a novel CKD target.
Maze Therapeutics Inc Info
Ticker SymbolMAZE
Company nameMaze Therapeutics Inc
IPO dateJan 31, 2025
CEOColoma (Jason V)
Number of employees125
Security typeOrdinary Share
Fiscal year-endJan 31
Address171 Oyster Point Boulevard, Suite 300
CitySOUTH SAN FRANCISCO
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code94080
Phone16508505070
Websitehttps://www.mazetx.com/
Ticker SymbolMAZE
IPO dateJan 31, 2025
CEOColoma (Jason V)
Company Executives of Maze Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Jonathan E. Lim, M.D.
Dr. Jonathan E. Lim, M.D.
Independent Director
Independent Director
328.70K
--
Dr. Sekar (Sek) Kathiresan, M.D.
Dr. Sekar (Sek) Kathiresan, M.D.
Independent Director
Independent Director
103.72K
--
Mr. Atul Dandekar
Mr. Atul Dandekar
Chief Strategy and Business Officer
Chief Strategy and Business Officer
23.25K
+61.54%
Dr. Charles Homcy, M.D.
Dr. Charles Homcy, M.D.
Co-Founder, Director
Co-Founder, Director
--
--
Dr. Jason V. Coloma, Ph.D.
Dr. Jason V. Coloma, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Harold Bernstein, M.D., Ph.D.
Dr. Harold Bernstein, M.D., Ph.D.
President - Research and Development, Chief Medical Officer
President - Research and Development, Chief Medical Officer
--
--
Ms. Courtney J. Phillips
Ms. Courtney J. Phillips
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
--
--
Dr. Nancy C. Andrews, M.D., Ph.D.
Dr. Nancy C. Andrews, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Jamie Brush, M.D.
Dr. Jamie Brush, M.D.
Independent Director
Independent Director
--
--
Mr. Alan B. Colowick, M.D.
Mr. Alan B. Colowick, M.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Jonathan E. Lim, M.D.
Dr. Jonathan E. Lim, M.D.
Independent Director
Independent Director
328.70K
--
Dr. Sekar (Sek) Kathiresan, M.D.
Dr. Sekar (Sek) Kathiresan, M.D.
Independent Director
Independent Director
103.72K
--
Mr. Atul Dandekar
Mr. Atul Dandekar
Chief Strategy and Business Officer
Chief Strategy and Business Officer
23.25K
+61.54%
Dr. Charles Homcy, M.D.
Dr. Charles Homcy, M.D.
Co-Founder, Director
Co-Founder, Director
--
--
Dr. Jason V. Coloma, Ph.D.
Dr. Jason V. Coloma, Ph.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Harold Bernstein, M.D., Ph.D.
Dr. Harold Bernstein, M.D., Ph.D.
President - Research and Development, Chief Medical Officer
President - Research and Development, Chief Medical Officer
--
--
Revenue Breakdown
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2024
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
0.00
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, May 10
Updated: Sun, May 10
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Third Rock Ventures, LLC
9.80%
Frazier Life Sciences Management, L.P.
8.25%
Deep Track Capital LP
7.67%
ARCH Venture Partners
7.44%
Janus Henderson Investors
5.68%
Other
61.15%
Shareholders
Shareholders
Proportion
Third Rock Ventures, LLC
9.80%
Frazier Life Sciences Management, L.P.
8.25%
Deep Track Capital LP
7.67%
ARCH Venture Partners
7.44%
Janus Henderson Investors
5.68%
Other
61.15%
Shareholder Types
Shareholders
Proportion
Venture Capital
29.53%
Hedge Fund
22.51%
Investment Advisor/Hedge Fund
17.37%
Investment Advisor
14.65%
Private Equity
9.43%
Individual Investor
1.48%
Family Office
0.89%
Research Firm
0.69%
Bank and Trust
0.06%
Other
3.39%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
213
53.41M
97.33%
+12.39M
2025Q4
156
40.80M
84.78%
+941.72K
2025Q3
111
39.53M
83.57%
-194.63K
2025Q2
100
42.58M
97.22%
+13.88M
2025Q1
93
44.69M
102.04%
+15.27M
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Third Rock Ventures, LLC
5.42M
10.91%
--
--
Dec 31, 2025
Frazier Life Sciences Management, L.P.
4.57M
9.19%
--
--
Dec 31, 2025
Deep Track Capital LP
4.25M
8.54%
+297.53K
+7.53%
Dec 31, 2025
ARCH Venture Partners
4.12M
8.29%
--
--
Dec 31, 2025
Janus Henderson Investors
3.14M
6.32%
+2.39M
+317.97%
Dec 31, 2025
Andreessen Horowitz
1.70M
3.42%
--
--
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
1.64M
3.31%
+439.68K
+36.53%
Dec 31, 2025
VR Adviser, LLC
1.55M
3.12%
+317.80K
+25.82%
Dec 31, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Virtus LifeSci Biotech Clinical Trials ETF
1.64%
Invesco Dorsey Wright SmallCap Momentum ETF
0.53%
ALPS Medical Breakthroughs ETF
0.39%
iShares Micro-Cap ETF
0.12%
iShares Russell 2000 Value ETF
0.04%
ProShares UltraPro Russell2000
0.03%
ProShares Hedge Replication ETF
0.03%
iShares Russell 2000 ETF
0.02%
Proshares Ultra Russell 2000
0.02%
Schwab U.S. Small-Cap ETF
0.02%
View more
Virtus LifeSci Biotech Clinical Trials ETF
Proportion1.64%
Invesco Dorsey Wright SmallCap Momentum ETF
Proportion0.53%
ALPS Medical Breakthroughs ETF
Proportion0.39%
iShares Micro-Cap ETF
Proportion0.12%
iShares Russell 2000 Value ETF
Proportion0.04%
ProShares UltraPro Russell2000
Proportion0.03%
ProShares Hedge Replication ETF
Proportion0.03%
iShares Russell 2000 ETF
Proportion0.02%
Proshares Ultra Russell 2000
Proportion0.02%
Schwab U.S. Small-Cap ETF
Proportion0.02%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
